Show simple item record

dc.contributor.advisorHutt, Peter Bartonen_US
dc.contributor.authorKim, Sandraen_US
dc.date.accessioned2012-07-06T21:38:45Z
dc.date.issued2002en_US
dc.identifier.citationAtypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity (2002 Third Year Paper)en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8965593
dc.description.abstractThis paper discusses the impact of schizophrenia on American society and advocates for health care reform to address the lack of access by the mentally ill to a class of innovative drugs, called “atypical anti-psychotics.†Atypical anti-psychotic drugs, including clozapine, risperidone and olanzapine are crucial for the treatment of both the positive and negative symptoms of schizophrenia and should be made available as first-line treatments for schizophrenics. Current health care policies and reforms provide facially attractive benefits, but lack significant practical benefits, resulting in obstacles to access to these life-changing medications. Health care reforms providing adequate reimbursement for these medications, and thereby opening access to them on a first-line basis, would in fact relieve financial pressures on our health care system instead of creating further strain on scarce resources by reducing funds spent on hospitalization and other medical resources.en
dc.language.isoen_USen
dash.licenseLAAen_US
dc.subjectFood and Drug Lawen
dc.subjectdrugsen
dc.subjectschizophreniaen
dc.subjectanti-psychoticen
dc.titleAtypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parityen
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-07-06T21:38:45Z
dash.authorsorderedfalse


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record